RecruitingPhase 3NCT06394999

Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive


Sponsor

Leiden University Medical Center

Enrollment

1,186 participants

Start Date

May 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Participants in the study will use mifepristone 50 mg once-a-week for one year as a contraceptive. With this, we want to confirm that the chances of getting pregnant while using this contraceptive are very small. We also want to demonstrate that the use of mifepristone is safe, and it does not lead to any severe health problems. We expect fewer side effects compared to other frequently used contraceptives with hormones. Mifepristone does not contain these hormones. It is important to know how people experience that use of one tablet a week.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mifepristone 50 mg for people with female contraception. The study is currently recruiting participants at 14 locations. People eligible for this study include women aged 18 Years to 35 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMifepristone 50 mg

Once-weekly oral mifepristone 50 mg


Locations(14)

Noordwest Ziekenhuisgroep

Alkmaar, Netherlands

Ziekenhuisgroep Twente

Almelo, Netherlands

Flevoziekenhuis

Almere Stad, Netherlands

Amsterdam Universitair Medische Centra

Amsterdam, Netherlands

Medisch Spectrum Twente

Enschede, Netherlands

Admiraal De Ruyter Ziekenhuis

Goes, Netherlands

Martini Ziekenhuis

Groningen, Netherlands

Medisch Centrum Leeuwarden

Leeuwarden, Netherlands

Leiden University Medical Center

Leiden, Netherlands

Maastricht Universitair Medisch Centrum

Maastricht, Netherlands

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands

Franciscus Gasthuis

Rotterdam, Netherlands

Diakonessenhuis

Utrecht, Netherlands

Maxima Medisch Centrum

Veldhoven, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06394999


Related Trials